1.39

14.98% -0.245

After Hours: 1.40 0.01 +0.72%

Fate Therapeutics Inc (FATE)

Overview News Price History Option Chain Financials Discussions Forecast

Fate Therapeutics Inc stock is traded at $1.39, with a volume of 2.32M. It is down -14.98% in the last 24 hours and up +44.33% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Previous Close:

$1.635

Open:

$1.61

24h Volume:

2.32M

Relative Volume:

1.24

Market Cap:

$160.31M

Revenue:

$13.45M

Net Income/Loss:

$-178.23M

P/E Ratio:

-0.8424

EPS:

-1.65

Net Cash Flow:

$-132.53M

1W Performance:

-1.42%

1M Performance:

+44.33%

6M Performance:

+31.13%

1Y Performance:

-55.02%

1-Day Range:

$1.38

$1.63

1-Week Range:

$1.27

$1.66

52-Week Range:

$0.6611

$3.50

Fate Therapeutics Inc Stock (FATE) Company Profile

Name

Fate Therapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (637)

Phone

858.875.1803

Address

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Employee

181

Twitter

@fatethx

Next Earnings Date

2025-08-08

Latest SEC Filings

FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FATE Fate Therapeutics Inc	1.39	188.56M	13.45M	-178.23M	-132.53M	-1.65
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral
Jan-06-23	Downgrade	Stifel	Buy → Hold
Jan-06-23	Downgrade	Truist	Buy → Hold
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-10-22	Initiated	Canaccord Genuity	Buy
Aug-18-22	Resumed	Wells Fargo	Overweight
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-11-22	Resumed	BMO Capital Markets	Market Perform
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform
Dec-07-21	Initiated	Cowen	Outperform
Nov-09-21	Upgrade	Citigroup	Neutral → Buy
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jun-07-21	Upgrade	H.C. Wainwright	Neutral → Buy
May-07-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Jefferies	Buy
Feb-26-21	Initiated	BofA Securities	Buy
Feb-26-21	Downgrade	Wedbush	Outperform → Neutral
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-27-21	Resumed	H.C. Wainwright	Neutral
May-13-20	Initiated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-09-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-30-19	Reiterated	Mizuho	Buy
Dec-09-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-12-19	Initiated	SunTrust	Buy
Nov-06-19	Downgrade	Wells Fargo	Outperform → Market Perform
Oct-01-19	Initiated	Stifel	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-19	Initiated	Oppenheimer	Outperform
Jun-13-19	Initiated	Mizuho	Buy
Jun-07-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Buy
May-24-19	Resumed	Citigroup	Buy
Mar-28-19	Initiated	SVB Leerink	Outperform
Jan-03-19	Downgrade	Stephens	Overweight → Equal-Weight
Nov-05-18	Initiated	Jefferies	Buy
Aug-01-18	Initiated	Citigroup	Buy
Mar-06-18	Downgrade	H.C. Wainwright	Buy → Neutral

View All

Fate Therapeutics Inc Stock (FATE) Latest News

11:54 AM

Is Fate Therapeutics Inc. stock reversal real or fake2025 Market Trends & Daily Oversold Bounce Ideas - newser.com

11:54 AM

10:10 AM

Automated trading signals detected on Fate Therapeutics Inc.Trade Exit Summary & Reliable Price Breakout Alerts - newser.com

10:10 AM

08:24 AM

Advanced analytics toolkit walkthrough for Fate Therapeutics Inc.Market Trend Summary & Risk Managed Investment Signals - newser.com

08:24 AM

08:01 AM

Published on: 2025-10-13 07:01:23 - newser.com

08:01 AM

03:44 AM

Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsBull Run & Free Long-Term Investment Growth Plans - newser.com

03:44 AM

Oct 12, 2025

What technical signals suggest for Fate Therapeutics Inc. stockJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com

Oct 12, 2025

Oct 10, 2025

What’s next for Fate Therapeutics Inc. stock priceWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com

Oct 10, 2025

Risk vs reward if holding onto Fate Therapeutics Inc.July 2025 Review & Free Safe Capital Growth Stock Tips - newser.com

Oct 10, 2025

Historical volatility pattern of Fate Therapeutics Inc. visualizedEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com

Oct 10, 2025

Oct 09, 2025

Real time social sentiment graph for Fate Therapeutics Inc.Trade Volume Report & Verified Entry Point Signals - newser.com

Oct 09, 2025

Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 08, 2025